Business Context and Reporting Period
Company: Repro-Med Systems, Inc. (Note: Input metadata referenced "KORU Medical Systems," but the filing text identifies the registrant as Repro-Med Systems, Inc.)
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: August 31, 2008
Business Overview: The company designs and manufactures medical devices, primarily the Freedom60 Syringe Infusion System for ambulatory medication delivery and the RES-Q-VAC Emergency Airway Suction System. The company is classified as a smaller reporting company.
Key Financial Metrics
| Metric | Three Months Ended Aug 31, 2008 | Six Months Ended Aug 31, 2008 | Six Months Ended Aug 31, 2007 |
|---|---|---|---|
| Net Sales | $936,495 | $1,636,471 | $1,003,364 |
| Net Income (Loss) | $279,529 | $344,167 | $(124,153) |
| Net Income Available to Common | $275,529 | $340,167 | $(128,153) |
| Net Cash from Operating Activities | N/A | $68,214 | $(9,160) |
| Cash Balance (End of Period) | $151,854 | $151,854 | $70,046 |
| Total Assets | $1,479,295 | $1,479,295 | $1,304,987 |
| Total Liabilities | $1,491,122 | $1,491,122 | $1,690,010 |
| Stockholders' Deficit | $(11,827) | $(11,827) | $(385,023) |
Debt & Liquidity: As of August 31, 2008, the company held $151,854 in cash. Total current liabilities were $853,405, including a $394,267 note payable to a financial institution and $15,000 in notes payable to related parties. The company reported a working capital surplus of approximately $349,526 ($1,202,931 current assets less $853,405 current liabilities).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 55% ($330,549) for the three months ended August 31, 2008, compared to the same period in 2007. For the six-month period, sales increased 63% ($633,107).
- Profitability Turnaround: The company shifted from a net loss of $124,153 in the six months ended August 31, 2007, to a net profit of $344,167 in the current period. This represents a total improvement of $468,320.
- Product Performance:
- Freedom60: Sales increased 86% (quarterly) and 104% (six-month) driven by Medicare specifying the device for subcutaneous immune globulin (SCIG) reimbursement.
- RES-Q-VAC: Sales increased 30% (quarterly) and 34% (six-month), with international sales up 31.4% offsetting a 37% domestic decline in the six-month period.
- Expense Management: Selling, General, and Administrative (SG&A) expenses decreased $26,227 quarter-over-quarter due to the absence of legal mediation fees incurred in the prior year. Research and Development expenses decreased significantly due to resource reallocation to sales.
- Interest Expense: Interest expense decreased $85,525 for the six-month period due to the payoff of high-interest bank notes and capital leases.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Management anticipates continued sales growth in the SCIG market as the market develops and new enhancements to the Freedom60 are introduced.
- The company received a $150,000 grant from the Trade Adjustment Assistance Program (matched 50-50) to assist with marketing, ISO, and regulatory affairs.
- Management believes current cash flow and capital resources are sufficient to meet financial obligations for the next twelve months, provided sales continue at current rates.
Risks and Contingencies:
- Reimbursement Risk: Sales are heavily dependent on Medicare reimbursement policies. There is no assurance that Medicare will continue to provide reimbursement or that it will not allow reimbursement for competitive devices.
- Competition: The company faces competition from lower-cost Chinese devices (e.g., Ambu Res Cue Pump) and established players like Laerdal. New drugs (e.g., Hyaluronidase) could alter market conditions.
- Liquidity: While currently positive, the company has historically faced liquidity constraints and relies on the success of specific product lines.
- Regulatory: Success depends on FDA approvals and adherence to government regulations in the home health care industry.
Investor Verification Checklist
- Revenue Concentration: Verify the extent of reliance on the Freedom60 product line and the specific impact of Medicare HCPCS code E0779 on future revenue stability.
- Debt Structure: Review the terms of the $394,267 note payable to the financial institution and the $409,000 in notes payable to related parties to understand repayment schedules and interest obligations.
- Grant Utilization: Confirm the status and disbursement schedule of the $150,000 Trade Adjustment Assistance Program grant.
- Stock-Based Compensation: Note that net income includes significant non-cash stock-based compensation ($24,209 for the quarter; $24,209 for the six months), which should be adjusted for when analyzing cash profitability.
- Market Competition: Assess the threat of lower-cost competitors in the RES-Q-VAC market and potential changes in SCIG drug administration methods.